Biodesix, Inc. (BDSX)

NASDAQ: BDSX · IEX Real-Time Price · USD
1.690
+0.030 (1.81%)
Jul 12, 2024, 4:00 PM EDT - Market closed
1.81%
Market Cap 193.82M
Revenue (ttm) 54.85M
Net Income (ttm) -47.06M
Shares Out 114.69M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 107,499
Open 1.660
Previous Close 1.660
Day's Range 1.630 - 1.695
52-Week Range 1.030 - 2.210
Beta 1.20
Analysts Strong Buy
Price Target 3.15 (+86.39%)
Earnings Date Aug 5, 2024

About BDSX

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lu... [Read more]

Sector Healthcare
IPO Date Oct 28, 2020
Employees 217
Stock Exchange NASDAQ
Ticker Symbol BDSX
Full Company Profile

Financial Performance

In 2023, Biodesix's revenue was $49.09 million, an increase of 28.46% compared to the previous year's $38.21 million. Losses were -$52.15 million, -20.32% less than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for BDSX stock is "Strong Buy." The 12-month stock price forecast is $3.15, which is an increase of 86.39% from the latest price.

Price Target
$3.15
(86.39% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Biodesix Named to Inc. Magazine's 2024 “Best Workplaces”

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine's Best Wor...

26 days ago - Business Wire

Biodesix to Participate in Two Investor Conferences in June

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Exe...

6 weeks ago - Business Wire

Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced that new data will be present...

7 weeks ago - Business Wire

Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced its financial and opera...

2 months ago - Business Wire

Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chie...

2 months ago - Business Wire

Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release fi...

2 months ago - Business Wire

Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was prese...

3 months ago - Business Wire

Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement

LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced the pricing of its underwritten offering of 17,3...

3 months ago - Business Wire

Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center

LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung diseases, today announced that it has entered into a new master collabora...

3 months ago - Business Wire

Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions and services company, today provided a corporate update and announced its fin...

4 months ago - Business Wire

Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference

LOUISVILLE, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chie...

4 months ago - Business Wire

Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release finan...

5 months ago - Business Wire

Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw Method

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today the validation and launch ...

8 months ago - Business Wire

Biodesix to Participate in Two Upcoming Investor Conferences in November

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Execut...

8 months ago - Business Wire

Biodesix Announces Third Quarter 2023 Results and Highlights

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operatin...

8 months ago - Business Wire

Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus on lung disease, announced today that it will release finan...

9 months ago - Business Wire

Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be pres...

10 months ago - Business Wire

Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that two abstr...

11 months ago - Business Wire

Biodesix to Participate in Two Upcoming Investor Conferences in September

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, ...

11 months ago - Business Wire

Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that a new ana...

11 months ago - Business Wire

Biodesix Announces Second Quarter 2023 Results and Highlights

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial ...

1 year ago - Business Wire

Biodesix to Participate in the Canaccord Genuity 43rd Annual Growth Conference

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hut...

1 year ago - Business Wire

Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will r...

1 year ago - Business Wire

Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the prosp...

1 year ago - Business Wire

Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Cente...

1 year ago - Business Wire